gallamine triethiodide has been researched along with am 281 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukaya, M; Fukudome, Y; Kano, M; Manabe, T; Matsui, M; Ohno-Shosaku, T; Omori, Y; Taketo, MM; Tsubokawa, H; Watanabe, M | 1 |
1 other study(ies) available for gallamine triethiodide and am 281
| Article | Year |
|---|---|
Two distinct classes of muscarinic action on hippocampal inhibitory synapses: M2-mediated direct suppression and M1/M3-mediated indirect suppression through endocannabinoid signalling.
Topics: Animals; Animals, Newborn; Benzoxazines; Blotting, Western; Brain; Calcium Channel Blockers; Cannabinoid Receptor Modulators; Carrier Proteins; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Endocannabinoids; GABA Plasma Membrane Transport Proteins; Gallamine Triethiodide; Heterozygote; Hippocampus; Immunohistochemistry; In Vitro Techniques; Membrane Proteins; Membrane Transport Proteins; Mice; Mice, Knockout; Morpholines; Muscarinic Agonists; Naphthalenes; Neural Inhibition; Nicotinic Antagonists; Oxotremorine; Patch-Clamp Techniques; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Receptor, Muscarinic M1; Receptor, Muscarinic M2; Receptor, Muscarinic M3; Signal Transduction; Synapses | 2004 |